New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:04 EDTISISIsis Pharmaceuticals announces results of antisense targeting of HBV
Isis Pharmaceuticals announced that treatment with an antisense compound targeting hepatitis B virus produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection. These preclinical data demonstrate that antisense targeting of HBV RNA could be an effective approach to treating patients with chronic HBV infection. In this study, an antisense compound targeting HBV produced dose-dependent reductions of HBV-associated antigens, including HBsAg, which is present in both acute and chronic infections and is associated with a poor prognosis in patients with chronic HBV infection. In addition, other measures of viral infection were reduced in both the liver and serum in this mouse model of disease.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
10:40 EDTISISIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
07:07 EDTISISIsis Pharmaceuticals announces results from ISIS-TTRRx study
Subscribe for More Information
July 22, 2015
19:26 EDTISISIsis Pharmaceuticals announces positive clinical data of ISIS-APO(a)Rx published
Subscribe for More Information
July 21, 2015
07:13 EDTISISIsis Pharmaceuticals initiates Phase 1/2a clinical study of ISIS-HTT Rx
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use